ArticleInternational journal of molecular sciences2015
Metastatic melanoma cells evade immune detection by silencing STAT1.
Article in International journal of molecular sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Comprehensive analyses of potential key genes in active tuberculosis: A systematic review.Medicine · 2021Pooled it
- ETS1 Orchestrates a Hybrid EMT Program Driving Metastasis and Immune Evasion.Cancer research · 2026Article
- Intestinal Epithelial MHC-II at the Interface of Microbiota, Immunity, and Inflammation.International journal of molecular sciences · 2026Review
- STAT1 accelerates cutaneous melanoma progression through TUBB4A expression regulation.Molecular medicine reports · 2026Article
- Article
- CD24, NFIL3, FN1, and KLRK1 signature predicts melanoma immunotherapy response and survival.Journal of molecular medicine (Berlin, Germany) · 2025Article
- Article
- Multi-omics-based subtyping of melanoma suggests distinct immune and targeted therapy strategies.Frontiers in immunology · 2025Article
- Pan-cancer analysis of oncogenic role of CEP55 and experiment validation in clear cell renal cell carcinoma.Scientific reports · 2024Article
- Anti-cancer potential of casein and its derivatives: novel strategies for cancer treatment.Medical oncology (Northwood, London, England) · 2024Review
- PABPC1L Induces IDO1 to Promote Tryptophan Metabolism and Immune Suppression in Renal Cell Carcinoma.Cancer research · 2024Article
- Primary cilia contribute to the aggressiveness of atypical teratoid/rhabdoid tumors.Cell death & disease · 2022Article
- The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma.Cellular oncology (Dordrecht, Netherlands) · 2022Article
- The downregulation of type I IFN signaling in G-MDSCs under tumor conditions promotes their development towards an immunosuppressive phenotype.Cell death & disease · 2022Article
- Ruxolitinib induces apoptosis of human colorectal cancer cells by downregulating the JAK1/2-STAT1-Mcl-1 axis.Oncology letters · 2021Article
- Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response.The Journal of clinical investigation · 2021Review
- Exploration of the Immune-Related Signatures and Immune Infiltration Analysis in Melanoma.Analytical cellular pathology (Amsterdam) · 2021Article
- STAT1 as a potential prognosis marker for poor outcomes of early stage colorectal cancer with microsatellite instability.PloS one · 2020Article
- Transmembrane and Ubiquitin-Like Domain Containing 1 Protein (TMUB1) Negatively Regulates Hepatocellular Carcinoma Proliferation via Regulating Signal Transducer and Activator of Transcription 1 (STAT1).Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Biological Hallmarks of Cancer in Alzheimer's Disease.Molecular neurobiology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcriptional activation of major histocompatibility complex (MHC) I and II molecules by the cytokine, interferon γ (IFN-γ), is a key step in cell-mediated immunity against pathogens and tumors. Recent evidence suggests that suppression of MHC I and II expression on multiple tumor types plays important roles in tumor immunoevasion. One such tumor is malignant melanoma, a leading cause of skin cancer-related deaths. Despite growing awareness of MHC expression defects, the molecular mechanisms by which melanoma cells suppress MHC and escape from immune-mediated elimination remain unknown. Here, we analyze the dysregulation of the Janus kinase (JAK)/STAT pathway and its role in the suppression of MHC II in melanoma cell lines at the radial growth phase (RGP), the vertical growth phase (VGP) and the metastatic phase (MET). While RGP and VGP cells both express MHC II, MET cells lack not only MHC II, but also the critical transcription factors, interferon response factor (IRF) 1 and its upstream activator, signal transducer and activator of transcription 1 (STAT1). Suppression of STAT1 in vitro was also observed in patient tumor samples, suggesting STAT1 silencing as a global mechanism of MHC II suppression and immunoevasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.